Please login to the form below

Not currently logged in
Email:
Password:

GSK-Pfizer HIV venture receives trial boost for Isentress rival

ViiV Healthcare's once-daily dolutegravir could offer preferable option to Merck’s twice-daily formula

ViiV Healthcare's investigational HIV therapy dolutegravir is as effective as Merck & Co's Isentress (raltegravir), according to a phase III head-to-head study.

ViiV, a joint venture between GlaxoSmithKline (GSK) and Pfizer, is co-developing dolutegravir with Japanese pharma company Shionogi. The once-daily integrase inhibitor aims to prevent the HIV virus from entering an individual's immune cells, stopping its replication process.

The drug's once-daily treatment regimen could give it the edge over Merck's Isentress, which is also an integrase inhibitor but has to be taken twice-daily, now that both drugs have been shown to be similarly safe and effective.

The data comes from the SPRING-2 study, which demonstrated that after 48 weeks, 88 per cent of study participants on dolutegravir were able to suppress to virus compared to 85 per cent of participants on Isentress. Both treatments were given along with two nucleoside reverse transcriptase inhibitors (NRTIs).

The primary endpoint of virological suppression was the proportion of study participants with undetectable HIV-1 RNA through 48 weeks.

The study, which involved 822 treatment-naïve participants, also found tolerability for the two drugs was comparable, with rates of adverse events and nausea similar in both trial arms.

Trial data from three more phase III studies involving dolutegravir are expected in 2012, which GSK said will allow "further determination" of the drug's profile.

“This marks an important milestone for the development of dolutegravir and the Shionogi-ViiV Healthcare joint venture,” said Dr Tsutae Nagata, chief medical officer, Shionogi.

“We look forward to completing further phase III studies in a variety of clinical settings in order to fully understand the potential clinical benefit for a range of HIV patient populations.”

If approved, analysts have said that ViiV's drug could have revenues of more than $1bn a year, with patients and healthcare professionals preferring its simpler once-daily dosing formula. Isentress made $1.36bn for Merck during 2011.

2nd April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
ICC HC

We started life as The Integrated Communications Company. Of course back then ‘integrated’ actually meant something. Today, we take it...

Latest intelligence

14_ipad_lowres.jpg
Do your customers feel that you’re listening to them?
When answering to data, excellent digital communication can create much stronger relationships between reps and customers....
Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...

Infographics